61 related articles for article (PubMed ID: 24780097)
41. Differential effect of tumor necrosis factor-alpha and herpes simplex virus type 1 on the Tat-targeted inhibition of human immunodeficiency virus type 1 replication.
Popik W; Pitha PM
Virology; 1994 Aug; 202(2):521-9. PubMed ID: 8030218
[TBL] [Abstract][Full Text] [Related]
42. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
43. A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties.
Chaubey B; Tripathi S; Ganguly S; Harris D; Casale RA; Pandey VN
Virology; 2005 Jan; 331(2):418-28. PubMed ID: 15629784
[TBL] [Abstract][Full Text] [Related]
44. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
[TBL] [Abstract][Full Text] [Related]
45. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
46. Guanine α-carboxy nucleoside phosphonate (G-α-CNP) shows a different inhibitory kinetic profile against the DNA polymerases of human immunodeficiency virus (HIV) and herpes viruses.
Balzarini J; Menni M; Das K; van Berckelaer L; Ford A; Maguire NM; Liekens S; Boehmer PE; Arnold E; Götte M; Maguire AR
Biochem Pharmacol; 2017 Jul; 136():51-61. PubMed ID: 28390939
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
48. Uptake of dicyanogold(i) by h9 cells.
Roy PW; Elder RC; Tepperman K
Met Based Drugs; 1994; 1(5-6):521. PubMed ID: 18476279
[No Abstract] [Full Text] [Related]
49. Anti-human immunodeficiency virus type 1 agent alpha-hydroxy glycineamide enters the target cells via a mechanism of passive diffusion.
Youssefi M; Vahlne A
J Pharm Pharmacol; 2014 Oct; 66(10):1388-93. PubMed ID: 24780097
[TBL] [Abstract][Full Text] [Related]
50. GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.
Jejcic A; Höglund S; Vahlne A
Retrovirology; 2010 Mar; 7():20. PubMed ID: 20230608
[TBL] [Abstract][Full Text] [Related]
51. Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.
Andersson E; Horal P; Jejcic A; Höglund S; Balzarini J; Vahlne A; Svennerholm B
Antimicrob Agents Chemother; 2005 Jan; 49(1):40-4. PubMed ID: 15616273
[TBL] [Abstract][Full Text] [Related]
52. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
[TBL] [Abstract][Full Text] [Related]
53. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.
Su J; Andersson E; Horal P; Naghavi MH; Palm A; Wu YP; Eriksson K; Jansson M; Wigzell H; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):1-7. PubMed ID: 11213928
[TBL] [Abstract][Full Text] [Related]
54. Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology.
Abdurahman S; Végvári A; Levi M; Höglund S; Högberg M; Tong W; Romero I; Balzarini J; Vahlne A
Retrovirology; 2009 Apr; 6():34. PubMed ID: 19356241
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
